a n a ly s i s Human papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCCs) are deadly and common cancers. Recent genomic studies implicate multiple genetic pathways, including cell signaling, cell cycle and immune evasion, in their development. Here we analyze public data sets and uncover a previously unappreciated role of epigenome deregulation in the genesis of 13% of HPV-negative HNSCCs. Specifically, we identify novel recurrent mutations encoding p.Lys36Met (K36M) alterations in multiple H3 histone genes. histones. We further validate the presence of these alterations in multiple independent HNSCC data sets and show that, along with previously described NSD1 mutations, they correspond to a specific DNA methylation cluster. The K36M substitution and NSD1 defects converge on altering methylation of histone H3 at K36 (H3K36), subsequently blocking cellular differentiation and promoting oncogenesis. Our data further indicate limited redundancy for NSD family members in HPV-negative HNSCCs and suggest a potential role for impaired H3K36 methylation in their development. Further investigation of drugs targeting chromatin regulators is warranted in HPVnegative HNSCCs driven by aberrant H3K36 methylation.
HNSCCs are a heterogeneous group of tumors that develop through chemically (as a result of tobacco and/or alcohol abuse) or virally induced carcinogenesis after infection with high-risk HPV 1 . They represent the seventh most frequent cancer worldwide, with ~600,000 new cases per year 2 , and occur throughout the oral cavity, hypopharynx, oropharynx, nasopharynx or larynx. Tumors are often locally advanced, invading proximal structures at diagnosis, or show spread to cervical lymph nodes or distant metastases. Despite several advances and innovations in multimodality treatment, survival rates of locally advanced HNSCCs have not substantially improved, and the prognosis for relapsed or metastatic tumors remains dismal 3 .
Several studies, including a recent comprehensive genomic profiling of a vast number of tumors by The Cancer Genome Atlas Project (TCGA), have shown that HPV-negative and HPV-positive HNSCCs represent distinct disease entities [4] [5] [6] . The latter, which arises mainly in the oropharynx (tonsils and base of tongue), is associated with a substantially improved outcome and harbors distinct molecular alterations 3, 6, 7 . The vast majority of HPV-negative tumors have lossof-function TP53 mutations and CDKN2A inactivation. Integrated genomic and DNA methylation analyses indicate a high level of heterogeneity in this entity, with the presence of several molecular clusters seemingly enriched for specific genetic alterations 6 . These studies also identified frequent alterations in pathways involving growth factor receptors, RAS and PI3K signaling, the cell cycle, cell death and differentiation and/or oxidative stress, which have thus become the focus of current research efforts and targeted therapies in HNSCCs [3] [4] [5] [6] [8] [9] [10] [11] [12] [13] . Interestingly, alterations in the gene encoding epigenetic modulator nuclear receptor-binding set domain protein 1 (NSD1) were recently identified in HPV-negative HNSCCs, but insights into whether or how these mutations could drive oncogenesis are lacking 6, 12 .
NSD1 is a member of the NSD family of mammalian histone methyltransferases, which are essential in development. NSD enzymes act as mono-and dimethyltransferases for H3K36 (ref. 14) , and SETD2 mediates trimethylation of H3K36, a chromatin mark associated with active transcription, gene splicing and DNA damage repair. Notably, aberrant regulation of H3K36 methylation has been identified in several neoplasms and could potentially promote oncogenesis [15] [16] [17] [18] [19] [20] . Germline hypomorphic NSD1 mutations lead to Sotos overgrowth syndrome, which is associated with a higher likelihood of cancer 21 . Somatic translocation and gain-of-function mutations involving NSD2 have been identified in leukemia and multiple myeloma, and NSD1 loss-of-function mutations have been described in lung cancers 22 . In acute myeloid leukemia (AML), the recurring t(5;11)(q35;p15.5) translocation fuses NSD1 to NUP98 (encoding nucleoporin-98) and leads to leukemogenesis through aberrant establishment of H3K36 methylation at specific genomic loci 16 . SETD2 mutations have also been described in a wide range of cancers 15, 19, 23 . Therefore, we reasoned that an abnormal epigenetic landscape, through alterations in the H3K36 methylation pathway, might constitute a mechanism in the development of HPV-negative HNSCCs. To investigate this, we performed an integrative analysis of existing genomic and DNA methylation data sets of HNSCCs to assess the functional impact of NSD1 Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas alterations and investigated the presence of other genetic alterations affecting the post-translational modifications of histones including H3K36. We found an epigenetically distinct subgroup in HPV-negative HNSCCs, where the main genetic alterations converge to specifically disrupt H3K36 methylation, potentially driving oncogenesis.
RESULTS

Reanalysis of the TCGA HNSCC data set
To assess the prevalence and nature of the genetic alterations affecting the epigenome in HNSCCs, we analyzed available HNSCC data with reported results from next-generation sequencing and DNA methylation profiling [4] [5] [6] 10, 11 . The TCGA data set, the largest generated on HNSCCs, had DNA methylation data (Infinium HumanMethylation450 BeadChip arrays) available for 528 samples, whole-exome sequencing (WES) for 526 samples and RNA sequencing for 520 samples. A total of 518 samples were profiled on all three platforms (Supplementary Fig. 1 ). We performed unsupervised hierarchical clustering of DNA methylation data ( Fig. 1) and identified a subgroup previously found to be enriched in NSD1 mutations. This subgroup comprised 61 samples, 44 of which carried damaging single nucleotide variants in NSD1 annotated in the initial TCGA analysis 6 (Supplementary Fig. 2 and Supplementary Table 1) . Upon closer inspection of the primary data, we found that other tumors within this cluster had more complex genomic events, including large chromosomal deletions encompassing this gene (n = 2), focal deletions within NSD1 (n = 2) and splicing defects (n = 1). Analysis of RNA-seq data showed absent NSD1 transcripts in two samples with noninterpretable WES data. In one sample, no conclusion could be drawn on NSD1 mutational status, as only methylation data were available (Supplementary Table 2 and Supplementary  Fig. 3) . Overall, the reanalysis indicated that 51/61 (84%) of samples within this methylation cluster carried NSD1 alterations. Notably, the majority of missense mutations in NSD1 in this cluster were located close to or within the functional SET domain and were frequently Figure 1 H3K36M and NSD1 alterations define a specific HNSCC subgroup. Unsupervised hierarchical clustering of DNA methylation data identifies five HNSCC subgroups, including a subgroup comprised of NSD1 or H3K36M alterations (labeled the H3K36 cluster). The H3K36 cluster is enriched in HPV-negative, TP53 mutant and heavy-smoking patients. Those tumors are found in the larynx and oral cavity. An HPV-positive, TP53 wild-type subgroup (HPV+) was apparent as well as three other subgroups (A, B and C). Gray and white bars for clinical variables (HPV status, anatomical location) indicate no hit or not available, respectively. a n a ly s i s a n a ly s i s associated with additional truncating mutations in the same samples ( Supplementary Fig. 2c ). In silico prediction of the functional impact of these mutations 24 suggests that they compromise the methyltransferase activity of NSD1 (Supplementary Table 1 ). Two of these missense mutations were previously reported in Sotos syndrome, a genetic disorder associated with germline NSD1 mutations 21 including one encoding p.Arg2005Gln, which has been shown to specifically ablate H3K36 methyltransferase activity 25 . The methylation-based clustering also clearly identified an HPV-positive TP53 wild-type tumor subgroup, which is known to constitute a distinct entity within HNSCCs, along with three other clusters (which we labeled A, B and C) that had no clear relationship to known alterations in HNSCC. NSD1 mutations were infrequent (4%), and were mostly missense and predicted to be less damaging in these clusters ( Fig. 1 and Supplementary Table 3) .
Identification of H3K36M alterations in HNSCC
Given the high prevalence of NSD1 mutations in this DNA methylation cluster, we investigated the mutational status of other genes involved in H3K36 methylation. We identified 11 samples harboring K36M-encoding mutations in various histone H3 genes. The mutations occurred in genes encoding the canonical histones H3.1 and H3.2 or the variant histone H3.3 ( Supplementary Fig. 2b and Supplementary Table 4) . Notably, 10 of the K36M alterations occurred within the DNA methylation cluster predominantly defined by NSD1 defects ( Fig. 1 and Supplementary Fig. 2a,b) . Taken together, H3K36M and NSD1 alterations accounted for all samples with available genomic data ( Supplementary Fig. 2a ) included in the DNA methylation-derived cluster (thus labeled the H3K36 cluster) and jointly represent 13% of HPV-negative HNSCC. Only one sample with an H3K36M alteration was observed outside the H3K36 cluster ( Fig. 1) . Other genes encoding potential H3K36 methyltransferases, including SETD2 and NSD2, were infrequently mutated in HNSCC, and samples with these mutations were spread across all HNSCC methylation subgroups ( Supplementary Fig. 4 ).
Clinical and molecular features of the H3K36 HNSCC subgroup
A number of altered genes have been identified to be enriched in HPV-negative HNSCCs [4] [5] [6] [8] [9] [10] 12, [26] [27] [28] , including TP53, EGFR, NOTCH1, PI3KCA and HRAS. We found that only the prevalence of TP53 and CASP8 varied significantly (P = 0.000621 and P = 0.00647, respectively, ANOVA) among HNSCC methylation subgroups ( Fig. 1 and Supplementary Fig. 4) . Similarly, there were no copy number alterations specific to the H3K36 cluster (data not shown). Consistent a n a ly s i s with the original TCGA report, we found tumors within this cluster to be strongly DNA hypomethylated (P < 1.99 × 10 −14 , Student's t-test) with no difference between H3K36M and NSD1 mutants (P = 0.36, Student's t-test) (Supplementary Fig. 5 ), suggesting that the unique DNA methylation signature of the H3K36 cluster is driven by defects in the H3K36 methylation pathway. NSD1-mutated samples within the H3K36 cluster showed lower NSD1 expression (Student's t-test, P = 0.0007), global DNA hypomethylation (Student's t-test, P = 1.41 × 10 −6 ) and more truncating mutations than did NSD1-mutated samples outside the H3K36 cluster (Supplementary Fig. 6 ).
The H3K36 cluster included tumors from heavy smokers or former heavy smokers who had recently stopped (Fig. 1) . When assessing the mutational burden in a given cluster, NSD1 mutant tumors were hypermutated (P < 0.0004, Student's t-test), whereas H3K36M samples had similar numbers of mutations per sample to that in other methylation clusters (Supplementary Fig. 7) . Notably, when we analyzed the somatic mutational pattern in relation to smoking, the signatures we obtained for each molecular entity showed that NSD1 but not H3K36M mutants had a mutational signature strongly associated with smoking ( Supplementary Fig. 8 ). Except for HPV-positive cancers, which are associated with a favorable outcome, there were no differences in tumor grade or outcome among HPV-negative HNSCCs (Supplementary Fig. 9 ). Moreover, we observed distinct anatomical locations for samples within the H3K36 cluster: all H3K36M tumors (100%, 10/10) occurred in the oral cavity, whereas NSD1 mutant tumors localized more often in the larynx (29/51, 57%, P < 0.007, χ 2 test) ( Fig. 2 and Supplementary Fig. 10) . No other clinical feature reached statistically significant enrichment (Supplementary Table 5 ). We also reanalyzed four other HNSCC WES data sets. In combination (196 samples in total), these studies enabled us to identify 14 NSD1 mutations, most of which were located in the larynx, and 1 HIST3H3H K36M-encoding mutation in the oral cavity 4, 5, 29, 30 . The 15 patients were HPV negative and were heavy smokers, consistent with our findings using the TCGA data set ( Fig. 1 and Supplementary Table 6 ).
Effects of mutations in modifiers of the epigenome
We assembled an independent cohort of 158 oropharyngeal (78 HPVpositive and 80 HPV-negative) HNSCCs with available tissue microarrays (TMAs) to determine the prevalence and impact of the K36M substitution on H3K36 methylation. Immunohistochemistry analysis identified three samples with typical nuclear staining of H3K36M, confirming expression of the mutant histone in HNSCC tumor tissues in this independent cohort (Fig. 3) . We have previously shown that the K36M substitution, although affecting only 1 of the 32 alleles encoding histone H3, acts as a dominant variant and inhibits the respective SET domain-containing methyltransferases, leading to decreased H3K36 dimethylation (H3K36me2) and trimethylation (H3K36me3) 31, 32 . As expected, immunohistochemical staining of the TMAs showed that samples carrying H3K36M have a drastic decrease in H3K36me2 and H3K36me3 levels (Fig. 3) . In tumor cores lacking NSD1 staining, global levels of H3K36me3 were mostly unchanged, and H3K36me2 levels were markedly reduced, as expected and in keeping with the role of NSD1 as a di-but not trimethyltransferase for H3K36 (Fig. 3) .
We also obtained two HNSCC cell lines carrying NSD1 truncating mutations (SCC-4 and SKN-3) and two cell lines bearing wild-type NSD1 (Fadu and PCI-4B). Immunoblotting and mass spectrometry analyses showed a marked decrease in H3K36me2 levels and relatively preserved H3K36me3 levels in histone extracts from the NSD1 mutant cell lines (Fig. 4) . Ectopic expression of H3K36M in HEK293 cells, two HNSCC cell lines bearing wild-type H3 and NSD1 and an NSD1-deficient HNSCC cell line led to significant decreases in H3K36me2 and H3K36me3 levels, similar to that observed in HNSCC patient TMA samples, and small interfering RNA (siRNA)-mediated knockdown of NSD1 specifically led to decreased H3K36me2 (Fig. 4b-e) . These findings suggest that both alterations may contribute to the progression of HNSCC through reduction of H3K36me2. It is notable that H3K36me2 levels were significantly altered in NSD1-mutant HNSCC samples and cell lines, despite showing relatively normal expression of NSD2 (P > 0.22, Student's t-test) (Fig. 4a and Supplementary Fig. 11) . Furthermore, knockdown of NSD1 resulted in a more pronounced reduction in H3K36me2 in HNSCC cells than in HEK293 cells (Fig. 4c) . n.s., not significant; *P < 0.05; **P < 0.01, Student's t-test. a n a ly s i s
These results highlight a major and nonredundant role of NSD1 in establishing H3K36me2 in HNSCC. Finally, we analyzed transcriptome data available with the TCGA data set and were able to identify a cluster that corresponds, to a large extent, to the DNA methylation-defined H3K36 subgroup ( Supplementary  Fig. 12 ), suggesting that altered methylation at H3K36 affects both the epigenome and transcriptome in HNSCC samples. We next performed differential expression analysis focusing on genes that are differentially expressed between H3K36 and other HNSCC subgroups 6,9,33,34 . Our results indicate that NSD1 and H3K36M mutants specifically suppressed the expression of genes involved in epidermal differentiation and keratinization processes (Supplementary Fig. 13 and Supplementary Table 7) . These findings mirror recent data in mouse mesenchymal progenitor cells, where overexpression of H3K36M resulted in a blockade in differentiation to the respective downstream lineages and induced undifferentiated sarcomas 32 .
DISCUSSION
In this study, we reanalyzed public genomic and epigenomic data sets from HNSCCs and identified a previously underappreciated role of epigenome deregulation in HNSCC tumorigenesis, specifically at H3K36. Our unsupervised clustering approach using DNA methylation data segregated 61 HNSCC samples into a cluster we labeled H3K36. This DNA methylation cluster exclusively contained samples carrying NSD1 mutations or K36M substitutions, reported here for the first time in HNSCC. Characterized by H3K36 alteration and DNA hypomethylation, this subgroup represents a significant subset of HPV-negative tumors (13%). Other clusters included a subgroup highly enriched in HPV-positive samples along with groups A, B and C, which did not harbor obviously defining clinico-pathological features or genetic alterations. Except for HPV-positive cancers, we did not observe any statistically significant differences in event-free survival among methylation clusters. This may be due to the relatively short median follow-up time (401 d) of the TCGA HNSCC cohort. When using a similar unsupervised clustering approach on RNA-seq data (Supplementary Fig. 12 ), we were also able to recuperate a group of samples enriched in NSD1 or H3K36M alterations, suggesting that the H3K36 cluster corresponds to a specific molecular entity.
In-depth analysis of the NSD1 locus in samples included in the H3K36 subgroup enabled us to identify alterations such as splicing defects and focal deletion of a small set of exons that were not detectable by standard automated approaches (Supplementary Table 2) . Moreover, a genebased approach previously failed to identify the enrichment of H3K36M substitutions, as they are observed across a wide array of histone H3 genes ( Supplementary Fig. 2b and Supplementary Table 4) . This is consistent with our previous work, which demonstrated that the effect of the H3K36M alteration is dominant and independent of H3 isoform 31, 32 (Figs. 3 and 4) . A complementary meta-analysis of earlier studies confirmed the prevalence of H3K36M and NSD1 alterations in HNSCC and their association with smoking and specific anatomical locations.
We replicated our genomic findings using an independent, previously unpublished cohort of HNSCC patient samples and showed that the mutant histone is expressed exclusively in tumor cells and leads to decreases in H3K36me2 and H3K36me3 (Fig. 3) . In contrast, NSD1 loss leads to decreased H3K36me2 (Figs. 3 and 4) , consistent with previous biochemical characterization of the enzyme as a specific H3K36 mono-and dimethyltransferase. Given the converging effects of NSD1 and H3K36M alterations on DNA methylation and H3K36me2, it appears that these alterations may help drive HNSCC pathogenesis through a common mechanism involving epigenome deregulation. H3K36M alterations have been observed in chondroblastoma 17 and more recently in pediatric soft-tissue tumors 32 . Our group also showed that, when introduced into mesenchymal progenitor cells, H3K36M was sufficient to induce undifferentiated sarcomas in mice by blocking cellular differentiation 32 . Our transcriptome analysis showed that genes specifically downregulated in the H3K36 subgroup are involved in cellular differentiation. These results support a model whereby an altered epigenetic landscape, mediated by impaired H3K36 methylation subsequent to the genetic alterations, arrests keratinocytes in a progenitor state refractory to differentiation stimuli. This differentiation blockade in turn synergizes with signaling and cell cycle deregulation to facilitate HNSCC development.
Notably, no NSD2 mutations were found in the H3K36 subgroup, and NSD1 deficiency was sufficient to decrease H3K36me2 in HNSCC cell lines despite normal expression of NSD2. Moreover, a recent report showed overexpression of NSD2 and increased H3K36me2 in a set of HNSCC samples 35 . Therefore, it appears that NSD1 and NSD2 may have nonredundant roles in certain cell types and that their effect can vary on the basis of the DNA methylation group. Further studies are warranted to investigate the distinct mechanisms by which gain or loss of H3K36me2 promotes HNSCC development.
The H3K36 cluster showed marked DNA hypomethylation compared to the other methylation subgroups. Interestingly, a recent study observed a DNA hypomethylation signature in Sotos syndrome, a monogenic disorder defined by germline NSD1 mutations 36 . Therefore, the DNA hypomethylation signature in the H3K36 subgroup is likely to be caused by genetic or H3K36M-mediated biochemical inactivation of NSD1. Several recent reports suggest a link between H3K36 methylation and the binding of de novo DNA methyltransferases (DNMT3A and DNTM3B) 37, 38 . The PWWP domain of DNMT3A, which is essential for its chromatin recruitment, specifically binds to H3K36me2 and H3K36me3. In agreement with this, the gene-body localization of Dnmt3b in mouse embryonic stem cells depends on Setd2-mediated H3K36me3 (ref. 38) . Therefore, the recruitment of DNMT3A and DNMT3B could be impaired in NSD1 mutant or H3K36M mutant tumors, leading to the global DNA hypomethylation phenotype observed in the H3K36 cluster.
Large and comprehensive genomic and epigenomic surveys of HNSCCs have increased understanding of the key driver mutations and heterogenic nature of this disease. Most of these studies emphasize the role of mutations affecting the cell cycle (in TP53 and CDKN2A) or signaling pathways, including growth factor receptors (FGFR, EGFR), RAS and PI3K pathways. Accordingly, a number of targeted therapies to attenuate signaling defects are under investigation in preclinical studies and clinical trials. However, recent studies in HNSCCs indicate that recurrent or metastatic tumors often fail to reproduce the mutational landscape of the primary tumor, specifically for the aforementioned targetable alterations 10 . In contrast, this evolutionary dynamic has not been observed in tumors carrying epigenetic drivers. Indeed, in the previously studied cancers that are promoted by mutations in genes encoding epigenetic modulators, such as DNMT3A, IDH 39 or histone H3 (ref. 40) , the epigenetic drivers are invariably present throughout the course of the disease. Our study uncovers a previously unsuspected role of impaired H3K36 methylation in HNSCCs. This finding underscores the need for further investigation into the mechanisms of epigenome deregulation in HNSCC tumorigenesis, as targeting epigenetic modifiers may be, when further validated by additional in vitro and in vivo studies, of therapeutic benefit for HNSCC patients with altered H3K36 methylation. 
ONLINE METHODS
DNA methylation clustering. We obtained level 1 (IDAT format) methylation data from the TCGA data portal for 528 HNSCC samples. We extracted raw beta values using the R package minfi 41 . We removed probes that contained or targeted SNPs as per Illumina's HumanMethylation450k Manifest. We performed hierarchical clustering using the 1,000 most variable sites. Distance (d) was assessed using d = 1 − r, where r is the Pearson productmoment coefficient. Clustering was performed using average linkage (unweighted pair group method with arithmetic mean (UPGMA)). To establish robustness of our groups, we tested their predictive ability using tenfold cross-validation. We computed the sample-by-sample correlation between the test and training and averaged on the training set subgroups. The test set labels were predicted according to the highest average correlation among the training set subgroup.
Somatic mutations.
We used all the somatic mutation calls from level 2 (MAF format) data from the TCGA data portal for 517 samples. We merged calls from the different sequencing centers, removed duplicates and converted the data (MAF to VCF) using a custom script. We annotated the resulting comprehensive mutation list using ANNOVAR 42 to obtain the resulting amino acid changes.
To address the prevalence of specific mutations in HPV-negative HNSCC methylation subgroups, we performed an ANOVA on the fraction of mutations observed in a target gene (number of mutations in target gene/total mutation count), excluding the HPV-positive subgroup. Every gene was treated independently, and P values were corrected for multiple testing using Bonferroni.
To predict the impact of NSD1 missense mutations on the protein function, we used Mutation Assessor, which evaluates the functional impact of an amino acid substitution on the basis of the evolutionary conservation of amino acid residues in a protein family multiple sequence alignment, assuming that mutations that affect conserved residues are more likely to be functional.
Alterations in the H3K36 cluster. Samples in the H3K36 cluster not carrying a somatic H3K36M or NSD1 alteration were manually assessed at the NSD1 locus. We identified large chromosomal deletions containing NSD1 (n = 2), focal deletion of a set of exons (n = 2) or splicing defects (n = 1). RNA-seq analysis showed absent NSD1 transcripts in two samples with noninterpretable WES data, and one sample in the cluster lacked genomic data (Supplementary Table 2 ). Lollipop plots were obtained from MutationMapper.
Clinical annotation. Smoking. We tested for association with smoking using the 4-factor definition given in the NCI CDE browser. To test for enrichment for smoking in H3K36 samples, we performed a Fisher's exact test on those factors.
Anatomical location. Anatomical locations were as follows (some anatomical locations are grouped to simplify visual representation): alveolar ridge; oral cavity (buccal mucosa, floor of mouth, hard palate, oral cavity, oral tongue); pharynx (base of tongue, hypopharynx, oropharynx); larynx; tonsil.
HPV status. In situ hybridization and p16 tests were combined together so that samples flagged as HPV-positive by either test would be considered as HPV-positive in our analysis, and vice versa for a negative diagnosis. Samples with no information were labeled as N/A.
Copy number analysis.
We obtained the level 3 CNV calls from the TCGA data portal for 520 samples. We used the nocnv_hg19.seg.txt as input for GISTIC 2.0 to extract significant CNVs. We clustered samples on the basis of CNV using a method previously described 6 . We considered NSD1 GISTIC value of −0.3 as sufficient evidence for loss of heterozygosity (LOH).
Mutation signature. To infer the mutagenic processes in HNSCC subgroups, we used the somatic mutations obtained as described above. Samples from each methylation-defined subgroup were merged because of the overall low number of mutations from WES. We appended mutations from eight TCGA cancers using the R package SomaticCancerAlterations. We extracted the mutational context (flanking nucleotides), extracted the somatic spectrum of each cancer and computed a 5-signature model using non-negative matrix alcohols, cleared in xylene and mounted with Eukitt Mounting Medium (EMS, 15320). Sections were scanned using an Aperio system. Scoring was done on 100 tumor cells from four separate fields for all four antibodies. Staining was considered conclusive for H3K36M when strong specific nuclear staining was seen in tumor cells with no immunoreactivity in adjacent stroma. In the absence of genotype data, a tumor was considered as possibly carrying NSD1 mutation if more than 70% of tumor cells lacked nuclear staining while normal NSD1 nuclear staining could be seen in infiltrating inflammatory cells or adjacent stroma. H3K36me3 and H3K36me2 stains were similarly scored to NSD1.
Histone acid extraction, histone derivatization and PTM analysis by nanoliquid chromatography-mass spectrometry (nano-LC-MS). Cells were lysed in hypotonic lysis buffer (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM DTT, protease inhibitors) for 1 h at 4 °C. H 2 SO 4 was added to 0.2 N followed by overnight rotation at 4 °C. After centrifugation (14,000 r.p.m. for 10 min at 4 °C), supernatants were collected, proteins were precipitated in 33% TCA, washed with acetone, and resuspended in deionized water.
Acid-extracted histones (15-25 µg) were resuspended in 100 mM ammonium bicarbonate (pH 8), derivatized using propionic anhydride and digested with trypsin as previously described 49 . The resulting histone peptides were desalted using C 18 Stage Tips, dried using a centrifugal evaporator and reconstituted using 0.1% formic acid in preparation for nano-LC-MS analysis.
Nano-LC was performed using a Thermo Scientific Easy nLC 1000 system equipped with a 75 µm × 20 cm in-house-packed column using Reprosil-Pur C18-AQ (3 µm; Dr. Maisch GmbH). Buffer A was 0.1% formic acid and buffer B was 0.1% formic acid in 100% acetonitrile. Peptides were resolved using a two-step gradient from 0% to 26% B over 45 min, then from 26% B to 98% B over 10 min at a flow rate of 300 nL/min. The HPLC was coupled online to an Orbitrap Elite mass spectrometer operating in the positive mode using a Nanospray Flex Ion Source (Thermo Scientific) at 2.40 kV. MS was performed using data-independent acquisition (DIA) as previously described 50 with slight modifications. Briefly, two full MS scans (m/z 300-1,100) were acquired in the orbitrap with a resolution of 120,000 (at 200 m/z) every 8 DIA MS/MS events, using isolation windows of 50 m/z each (for example, 300-350, 350-400 and so on). The full MS scan was performed twice within the same duty cycle to allow for a more resolved definition of the precursor peak profile. MS/MS events were acquired in the ion trap operating in normal mode. Fragmentation was performed using collision-induced dissociation (CID) in the ion trap mass analyzer with a normalized collision energy of 35. AGC target and maximum injection time were 10 6 and 50 ms for the full MS scan, and 10 4 and 150 ms for the MS/MS scan, respectively.
Mass-to-charge ratios were calculated for each modified form of H3 peptide. The area under the curve was calculated from extracted ion chromatograms using Xcalibur Qual Browser for each histone peptide mass-to-charge ratio using a 10 p.p.m. mass accuracy cutoff. Data from all detectable charge states were summed. The area for each modification state of a peptide was normalized against the sum of all peptides sharing the same sequence to give the relative abundance of each modified state. Three biological replicates were analyzed per condition, and the relative abundance of each peptide modification was averaged across runs. Statistical significance was determined using Student's t-test.
Data availability. All sequencing and methylation data were obtained from the TCGA Genomic Data Commons (https://gdc.cancer.gov/). The NCI CDE browser can be accessed at https://cdebrowser.nci.nih.gov/. Anatomical locations of cancers were grouped as described by the NIH National Cancer institute at http://www.cancer.gov/types/head-and-neck/head-neckfact-sheet#q1.
